BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

11083	Companies
243242	Keywords
171394	Articles
130959	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 01/21/2025 at 09:05, 1 year 8 months ago

BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
BioNxt Solutions Inc. relocates R&D activities to Gen-Plus CRDO in Munich, Germany, enhancing capabilities and fostering collaborations in drug delivery systems, neurodegenerative therapeutics, and biomedical tech

BioNxt Solutions Inc. Munich R&D Activities Drug Delivery Systems Gen-Plus CRDO
BRIEF

published on 12/19/2024 at 09:10, 1 year 9 months ago

BioNxt Solutions Expands Patent Portfolio for Drug Delivery Innovations

Multiple Sclerosis BioNxt Solutions Sublingual Delivery Patent Expansion Drug Innovation
BRIEF

published on 12/19/2024 at 09:10, 1 year 9 months ago

BioNxt Solutions élargit son portefeuille de brevets pour ses innovations en matière d'administration de médicaments

Sclérose En Plaques Innovation Pharmaceutique Solutions BioNxt Extension Du Brevet Administration Sublinguale
PRESS RELEASE

published on 12/19/2024 at 09:05, 1 year 9 months ago

BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP
BioNxt Solutions Inc. expands its intellectual property portfolio with new international patents for sublingual delivery technologies targeting autoimmune neurodegenerative diseases. The company aims to bring patient-friendly therapies to individuals affected by these diseases

BioNxt Solutions Inc. Intellectual Property Patents Autoimmune Neurodegenerative Diseases Sublingual Delivery Technologies
BRIEF

published on 12/09/2024 at 09:10, 1 year 9 months ago

BioNxt Solutions Advances BNT23001 for MS Treatment

Clinical Trials Drug Development Multiple Sclerosis BioNxt Solutions BNT23001
BRIEF

published on 12/09/2024 at 09:10, 1 year 9 months ago

BioNxt Solutions développe le BNT23001 pour le traitement de la sclérose en plaques

Essais Cliniques Sclérose En Plaques Développement De Médicaments Solutions BioNxt BNT23001
PRESS RELEASE

published on 12/09/2024 at 09:05, 1 year 9 months ago

BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
BioNxt Solutions Inc. achieves key milestones in the development of BNT23001, a sublingual thin-film formulation of Cladribine for Multiple Sclerosis treatment, paving the way for clinical trials and regulatory submissions in 2025

Clinical Trials BioNxt Solutions Inc. Multiple Sclerosis Sublingual Thin-Film BNT23001
BRIEF

published on 12/02/2024 at 09:10, 1 year 9 months ago

BioNxt Solutions Develops Sublingual Thin-Film for Semaglutide

Drug Delivery Innovation BioNxt Solutions Patient Compliance Sublingual Thin-Film Semaglutide
BRIEF

published on 12/02/2024 at 09:10, 1 year 9 months ago

BioNxt Solutions développe un film mince sublingual pour le sémaglutide

Solutions BioNxt Conformité Des Patients Semaglutide Couche Mince Sublinguale Innovation Dans L'administration Des Médicaments
PRESS RELEASE

published on 12/02/2024 at 09:05, 1 year 9 months ago

BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
BioNxt Solutions Inc. introduces sublingual thin-film oral dissolvable film (ODF) for Semaglutide, enhancing patient experience and improving drug delivery

Innovation Healthcare BioNxt Solutions Inc. Drug Delivery Semaglutide

Accesswire

Published on 09/25/2026 at 15:00, 2 hours 8 minutes ago

HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/25/2026 at 14:00, 3 hours 8 minutes ago

Karbon-X (OTCQB:KARX) to Present Global Growth Strategy and Showcase SkyXero at 26th MK-Equity Investment Conference in Munich
Published on 09/25/2026 at 13:00, 4 hours 8 minutes ago

Core Silver Announces Grant of Stock Options
Published on 09/25/2026 at 13:00, 4 hours 8 minutes ago

American Hotel Income Properties REIT LP Announces Corporate Update
Published on 09/25/2026 at 13:00, 4 hours 8 minutes ago

UraniumX Plans Winter Gravity Program at Murphy Lake as Q4 Assays Approach

View all ACCESSWIRE

EQS Group

Published on 09/25/2026 at 16:33, 34 minutes ago

Genel Energy PLC: Successful tap issue of bonds
Published on 09/25/2026 at 16:10, 58 minutes ago

Amundi Index Solutions: NOTICE TO SHAREHOLDERS
Published on 09/25/2026 at 16:00, 1 hour 8 minutes ago

Deutsche Beteiligungs AG: Balance sheet investment in Vected; hidden champion in optronics for defence and security
Published on 09/25/2026 at 15:50, 1 hour 18 minutes ago

Zentra Group plc: One Victoria – Replacement Building Contract Signed
Published on 09/25/2026 at 15:37, 1 hour 31 minutes ago

EQS-Adhoc: RAG-Stiftung: RAG-Stiftung regarding a potential takeover of Evonik by BASF

Les Echos

Published on 09/25/2026 at 07:00, 10 hours 8 minutes ago

ENGIE mobilise une aide exceptionnelle de 54 millions d'euros pour soutenir les ménages les plus fragiles face à la hausse des prix de l'énergie
Published on 09/24/2026 at 18:31, 22 hours 37 minutes ago

LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:10, 22 hours 58 minutes ago

Financial statements - 30 june 2026
Published on 09/24/2026 at 18:00, 23 hours 8 minutes ago

GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 23 hours 8 minutes ago

GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026

View all LES ECHOS COMFI WIRE